Primary hyperparathyroidism linked to bone fracture, stroke, and heart attack
Previous studies have linked primary hyperparathyroidism to osteoporosis and cardiovascular disease. However, since these studies have been few and small, the association has been debated.
Many complications
This study, published in the journal JAMA Network Open, is based on national register data from the Swedish National Board of Health and Welfare. All the 16,374 patients included were diagnosed with primary hyperparathyroidism sometime between 2006 and 2017. Each was compared with ten control individuals from the population born in the same year, of the same sex, and residing in the same county.
"We show that untreated primary hyperparathyroidism means a 51% higher risk of hip fracture and a 45% increase in heart attack or stroke risk. The kidney stone risk is almost quadrupled and, additionally, the risk of death is raised by 72%.
The increased likelihood of these complications highlights the importance of identifying patients with this hormonal disease," says Kristian Axelsson, researcher at the University of Gothenburg, resident in general medicine within the public primary care in Region Västra Götaland, and the study's first author.
Surgery reduces risks
An operation to remove the parathyroid glands (parathyroidectomy), entirely or partially, is the only definitive treatment for primary hyperparathyroidism. Patients who meet special criteria may undergo surgery. Careful monitoring is recommended for those who do not.
The study shows that the elevated risks of hip fracture, heart attack, and stroke decreased significantly for patients who underwent surgery.
"The study indicates that surgery clearly reduces the risk of osteoporosis fractures, fall injuries, and death in cardiovascular events, and these are vital findings that may lead to more patients being selected for surgery. Our results support the view that patients' cardiovascular risk, as well as the high fracture risk, should be considered in surgery decisions," says Mattias Lorentzon, Professor of Geriatric Medicine at the University of Gothenburg, Chief Physician at Sahlgrenska University Hospital, and senior author of the study.
To read the full article, check out the following link:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd